Barclays PLC Has $253,000 Stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Barclays PLC raised its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 13.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,972 shares of the company’s stock after acquiring an additional 4,028 shares during the quarter. Barclays PLC’s holdings in Lifecore Biomedical were worth $253,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Invesco Ltd. bought a new stake in shares of Lifecore Biomedical in the fourth quarter valued at about $4,128,000. Wells Fargo & Company MN boosted its position in shares of Lifecore Biomedical by 29.0% in the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company’s stock valued at $99,000 after acquiring an additional 3,012 shares during the period. Rangeley Capital LLC bought a new stake in shares of Lifecore Biomedical in the fourth quarter valued at about $325,000. Geode Capital Management LLC boosted its position in shares of Lifecore Biomedical by 14.7% in the fourth quarter. Geode Capital Management LLC now owns 685,746 shares of the company’s stock valued at $5,097,000 after acquiring an additional 88,061 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of Lifecore Biomedical in the fourth quarter valued at about $95,000. 83.36% of the stock is owned by institutional investors.

Lifecore Biomedical Stock Up 1.2%

LFCR stock opened at $6.97 on Monday. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The company has a market cap of $258.06 million, a PE ratio of -12.45 and a beta of 0.65. The business has a 50-day simple moving average of $6.41 and a 200 day simple moving average of $6.51. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Sell-side analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Aron R. English sold 15,847 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $7.01, for a total transaction of $111,087.47. Following the sale, the insider now owns 1,714,070 shares in the company, valued at approximately $12,015,630.70. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 32.20% of the stock is currently owned by company insiders.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.